Secondary biopsy of non-oncogenic-driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases.

abstract：:Malignant pleural mesothelioma is an extremely aggressive neoplasm of the pleura mainly attributable to asbestos exposure. Conventional medical, physical, and surgical treatments and their combinations are basically ineffective and just a few subjects experience some benefit. No definite guidelines can be provided in ...

journal_title：Thoracic cancer

authors： Ambrogi V,Mineo TC,Multidisciplinary Tor Vergata University Study Group for Malignant Pleural Mesothelioma.

更新日期：2012-11-01 00:00:00

abstract：:A clinical trial of immune checkpoint inhibitors for advanced non-small cell lung cancer reported an overall survival plateau with a long tail to the survival curve, suggesting that immune checkpoint inhibitors prolong survival. However, little evidence supports the efficacy of immune checkpoint inhibitors as neoadjuv...

journal_title：Thoracic cancer

authors： Sumi T,Uehara H,Masaoka T,Tada M,Keira Y,Kamada K,Shijubou N,Yamada Y,Nakata H,Mori Y,Chiba H

更新日期：2020-11-01 00:00:00

abstract：BACKGROUND:Computed tomography (CT)-guided percutaneous implantation of 125 Iodine radioactive seeds requires the precise arrangement of seeds by tumor shape. We tested whether selecting target areas, including subclinical areas around tumors, can influence locoregional recurrence in patients with non-small cell lung c...

journal_title：Thoracic cancer

authors： Yan WL,Lv JS,Guan ZY,Wang LY,Yang JK,Liang JX

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:A giant thoracic neoplasm is extremely rare and poorly understood. Our systemic study introduced computed tomography angiography (CTA) with three-dimensional (3D) reconstruction imaging and evaluated correlations between imaging, pathology, and surgical management. METHODS:Data from 45 patients undergoing s...

journal_title：Thoracic cancer

authors： Feng Z,Li M,Liu F,Peng Y,Ren W,Xie H,Peng Z

更新日期：2017-09-01 00:00:00

abstract：:ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

journal_title：Thoracic cancer

authors： Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...

journal_title：Thoracic cancer

authors： Kowal A,Wiśniewski A,Kuśnierczyk P,Jankowska R

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:This study investigated the correlations between CXCR4 and VEGF-C expression and lymph node metastasis in non-small cell lung cancer (NSCLC). METHODS:Tumor specimens, lymph nodes, and normal lung tissues were obtained from 110 NSCLC patients who underwent complete resection. Quantitative reverse transcripti...

journal_title：Thoracic cancer

authors： Bi MM,Shang B,Wang Z,Chen G

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...

journal_title：Thoracic cancer

authors： Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVES:To evaluate the oncological prognosis and neurological outcomes for patients with thymic epithelial tumors (TETs) after thymectomy. METHODS:Consecutive patients with TETs who underwent thymectomy at Beijing Hospital from January 2011 to December 2018 were retrospectively enrolled into the study. Clinical, p...

journal_title：Thoracic cancer

authors： Tian W,Sun Y,Wu Q,Jiao P,Ma C,Yu H,Huang C,Tong H

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:The prognostic values of preoperative neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) have been previously described. This study assessed the prognostic values of other pretreatment complete blood cell parameters in...

journal_title：Thoracic cancer

authors： Yuan C,Li N,Mao X,Liu Z,Ou W,Wang SY

更新日期：2017-07-01 00:00:00

abstract：:The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ...

journal_title：Thoracic cancer

authors： Du X,Shao Y,Qin HF,Tai YH,Gao HJ

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND:Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 amplification as a potential therapeutic target for LSCC are not well understood....

journal_title：Thoracic cancer

authors： Zhang X,Kong M,Zhang Z,Xu S,Yan F,Wei L,Zhou J

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because o...

journal_title：Thoracic cancer

authors： Kang DH,Chung C,Kim JO,Jung SS,Park HS,Park DI,Jung SY,Park M,Lee JE

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better progno...

journal_title：Thoracic cancer

authors： Kang J,Chen HJ,Zhang XC,Su J,Zhou Q,Tu HY,Wang Z,Wang BC,Zhong WZ,Yang XN,Chen ZH,Ding Y,Wu X,Wang M,Fu JG,Yang Z,Zhang X,Shao YW,Wu YL,Yang JJ

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:MicroRNA-128 (miR-128) serves as a regulator by inducing cancer cell apoptosis, differentiation, the epithelial-to-mesenchymal transition process, and tumor growth by mediating different targets. NIMA-related kinase 2 (NEK2) is aberrantly expressed in lung cancer. The miR-128/NEK2 pathway has been reported t...

journal_title：Thoracic cancer

authors： Zhao D,Han W,Liu X,Cui D,Chen Y

更新日期：2017-07-01 00:00:00

abstract：:Here, we report two cases of advanced non-small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma, cT1cN3M1c, stage IV...

journal_title：Thoracic cancer

authors： Shan Q,Wang H,Han X,Guo J,Wang Z

更新日期：2020-10-01 00:00:00

abstract：:Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non-small cell lung cancer and treated with orally...

journal_title：Thoracic cancer

authors： Luo J,Ni L,Wang M,Zhong W,Xiao Y,Zheng K,Hu P

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population. METHODS:The MeSO-CLICaP registry identified 302 patients with advanced MPM diagnose...

journal_title：Thoracic cancer

authors： Rojas L,Cardona AF,Trejo-Rosales R,Zatarain-Barrón ZL,Ramírez-Tirado LA,Ruiz-Patiño A,Campos Gómez S,Corrales L,Oblitas G,Bacon L,Martín C,de Lima VCC,Freitas HC,Mas L,Vargas C,Carranza H,Otero J,Pérez MA,González L,

更新日期：2019-03-01 00:00:00

abstract：BACKGROUND:Rab27A and Rab27B are the major components of vesicle fusion and trafficking in exosome secretion and play important roles in tumor progression and metastasis. In addition, Rab27A and Rab27B are associated with tumor prognosis. This study investigated the prognostic roles of Rab27A and Rab27B expression in p...

journal_title：Thoracic cancer

authors： Koh HM,Song DH

更新日期：2019-02-01 00:00:00

abstract：BACKGROUND:Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non-small cell lung cancer (NSCLC). There is a lack of high-level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literatur...

journal_title：Thoracic cancer

authors： Song W,Di S,Liu J,Fan B,Zhao J,Zhou S,Chen S,Dong H,Yue C,Gong T

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:To distinguish early-stage lung cancer from benign disease in pulmonary nodules, especially lesions with ground-glass opacity (GGO), we assessed gene mutations of ctDNA in peripheral blood using targeted next-generation sequencing (NGS). METHODS:Single pulmonary nodule patients without mediastinal lymph nod...

journal_title：Thoracic cancer

authors： Jiang N,Zhou J,Zhang W,Li P,Liu Y,Shi H,Zhang C,Wang Y,Zhou C,Peng C,Zhang W,Hao Y,Sun Q,Li Y,Zhao X

更新日期：2020-11-16 00:00:00

abstract：BACKGROUND:The number of patients diagnosed with early stage disease (T1a or T1b) has been increasing. This study was conducted to investigate the effect of esophagectomy (ES), endoscopic therapy (ET), and radiotherapy (RT) on long-term survival in elderly patients with cT1N0M0 esophageal cancer. METHODS:We searched t...

journal_title：Thoracic cancer

authors： Qin J,Peng Y,Chen W,Ma H,Zheng Y,Li Y,Wang J

更新日期：2019-07-01 00:00:00

abstract：:For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...

journal_title：Thoracic cancer

authors： Wang B,Yang J,Luo D,Qiao H,Xie Z,Zhang X,Wu Y

更新日期：2012-02-01 00:00:00

abstract：BACKGROUND:Growing evidence indicates that high phosphoserine phosphatase (PSPH) expression is associated with tumor prognosis in many types of cancers. However, the role of PSPH in non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to investigate the clinical significance of PSPH in NSCLC. M...

journal_title：Thoracic cancer

authors： Liao L,Yu H,Ge M,Zhan Q,Huang R,Ji X,Liang X,Zhou X

更新日期：2019-05-01 00:00:00

abstract：:A diagnostic work-up to evaluate possible mediastinal lymph node involvement in patients with non-small cell lung cancer (NSCLC) should be performed once suspected as a result of computed tomography. Cytological/histological verification is always compulsory. In recent years, diagnostic tools for mediastinal evaluatio...

journal_title：Thoracic cancer

authors： Dango S,Guenter J,Passlick B

更新日期：2010-07-01 00:00:00

abstract：BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...

journal_title：Thoracic cancer

authors： Kasahara N,Imai H,Naruse I,Tsukagoshi Y,Kotake M,Sunaga N,Kaira K,Maeno T,Asao T,Hisada T

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...

journal_title：Thoracic cancer

authors： Meijer TWH,Looijen-Salamon MG,Lok J,van den Heuvel M,Tops B,Kaanders JHAM,Span PN,Bussink J

更新日期：2019-12-01 00:00:00

abstract：BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two gro...

journal_title：Thoracic cancer

authors： Nie K,Zhang Z,You Y,Zhuang X,Zhang C,Ji Y

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates from the pleura and has a poor prognosis. Eligible patients can benefit from surgery, but their survival is affected by many factors. Therefore, we created a graphic model that could predict the prognosis of surgically treate...

journal_title：Thoracic cancer

authors： Zhuo M,Zheng Q,Chi Y,Jia B,Zhao J,Wu M,An T,Wang Y,Li J,Zhao X,Yang X,Zhong J,Chen H,Dong Z,Wang J,Zhai X,Wang Z

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:This study was conducted to evaluate the clinical utility of the oHSV1-hTERT-GFP circulating tumor cell (CTC) detection method in the peripheral blood of patients with lung cancer by comparing its sensitivity to the CellSearch CTC detection method. METHODS:The oHSV1-hTERT-GFP and CellSearch CTC detection me...

journal_title：Thoracic cancer

authors： Gao H,Liu W,Yang S,Zhang W,Li X,Qin H,Wang W,Zhao C

更新日期：2018-01-01 00:00:00